target="_blank" rel="nofollow" href="#ulink_034a8e2c-8731-5381-bfb9-1bdb060f5069">10Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N: Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549–555.
11Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, Galdiero M, Colao A: Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 2017;20:46–62.
12Aguilar C, Velázquez V, Gómez F, Gonzalez A, Lara A, Molina V, Rull J, Tapia R: Characteristics of patients with type 2 diabetes in Mexico. Results from a large population – based nationwide survey. Diabetes Care 2003;26:2021–2026.
13Unikrishnan R, Pradeepa R, Joshi SR, Mohon V: Type 2 diabetes: demystifying the global epidemic. Diabetes 2017;66:1432–1442.
14Biering H, Knoppe G, Lochs H: Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austr 2002;27:27–31.
15Stelmachovska-Banas M, Zdunowski P, Zgliczynski W: Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of symptoms? Endocrynol Pol 2009;60:20–24.
16Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M: Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 2011;14:231–235.
17Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, Vinogradova AV, Wolffenbuttel BH: Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 2014;3:93–98.
18Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, García-Dominguez A, Reza-Albarrán AA, Cuevas-Ramos D, Melgar V, Talavera J, Rivera-Hernandez AJ, Valencia-Méndez CV, Mercado M: Mexican Acromegaly Registry Group: The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab 2016;101:3997–4004.
19Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D: Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014;17:81–89.
20Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Ferone D, Colao A, Giordano C: The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013;98:E51–E59.
21Mercado M, Espinosa de los Monteros AL, Sosa E, Cheng S, Mendoza V, Hernandez I, Sandoval C, Guinto G, Molina M: Clinical-biohcemical correlations in acromegaly at diagnosis and the real prevalence of biochemically-discordant disease. Horm Res 2004;62:293–299.
22Bates AS, Evans AJ, Jones P, Clayton RN: Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf) 1995;42:417–423.
23Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, Chabre O, Francois P, Bertherat J, Cortet-Rudelli C, Chanson P: Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol 2017;176:645–655.
24Bates AS, Van’t Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293–299.
25Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M; Italian Study Group of Acromegaly: Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 2012;167:189–198.
26Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, López-Félix B, Guinto G: Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 2014;99:4438–4446.
27Giordano C, Ciresi A, Amato MC, et al: Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 2012;15:539–551.
28Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G: Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008;93:2639–2646.
29Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K, Yamada S, Takeuchi Y: Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur J Endocrinol 2011;164:467–473.
30Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plöckinger U, Strowski MZ: Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007;92:673–680.
31Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A: Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94:1500–1508.
32Jonas C, Maiter D, Alexopoulou O: Evolution of Glucose Tolerance After Treatment of Acromegaly: A Study in 57 patients. Horm Metab Res 2016;48:299–305.
33Mercado M, Espinosa E, Ramírez C: Current status and future directions of pharmacological therapy for acromegaly. Minerva Endocrinol 2016;41:351–365.
34Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group: Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014;99:791–799.
35Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A; Pasireotide C2402 Study
